Establishing A Breakthrough Endotoxin Removal Process For Recombinant Collagen Purification To Build A Safety Moat For Post-Aesthetic-Surgery Raw Materials
Many people experience recurrent redness, stinging, and a feeling of irritation after using recombinant collagen products. The root cause is often not the collagen itself, but residual endotoxins (lipopolysaccharides, LPS). Particularly in recombinant collagen produced using an E. coli expression system, endotoxins-components of the cell walls of Gram-negative bacteria-are highly heat-stable and can readily bind tightly to collagen. Even trace amounts of residual endotoxins may stimulate chronic skin inflammation, with reactions being particularly noticeable in sensitive skin and post-aesthetic-medical-procedure skin. Medical-grade recombinant collagen typically requires an endotoxin level of <0.5 EU/mg, whereas ordinary crude products may exceed this limit by dozens of times. Endotoxin removal is not merely a purification step; it is a critical requirement determining whether the raw material can enter markets such as Class III medical dressings, skin boosters, and post-procedure skin repair products. It requires systematic control throughout the entire process, balancing deep endotoxin removal with the preservation of the integrity, triple-helical structure, and biological activity of collagen.
Upstream Control at the Source: Reducing the Initial Endotoxin Load from the Upstream Process
The best approach to endotoxin removal is to reduce the total endotoxin burden at the source rather than relying entirely on downstream purification.
First, optimize the host strain and expression system.
E. coli expression systems offer high yields and low production costs, but naturally contain large amounts of lipopolysaccharide (LPS) endotoxin. Eukaryotic expression systems such as Pichia pastoris do not contain LPS and therefore represent naturally low-endotoxin expression platforms, making them suitable for the production of high-end medical-grade raw materials. If an E. coli system is selected, genetically engineered low-endotoxin strains can be developed to reduce the initial production of LPS. At the same time, codon optimization can be used to improve the soluble expression of collagen and reduce the massive release of endotoxins caused by cell disruption. Throughout plasmid preparation, endotoxin-free plasmid extraction kits should be used to prevent the introduction of exogenous endotoxins during the plasmid preparation process.
Second, GMP-compliant closed fermentation and pre-treatment clarification should be implemented. Fed-batch fermentation should be carried out in a fully closed and aseptic system with strict control of microbial contamination to minimize additional endotoxin production. The fermentation endpoint should also be optimized to prevent excessive aging and lysis of the host cells. The fermentation broth should first undergo primary clarification through depth filtration, centrifugation, and tangential flow microfiltration to remove cell debris, host-cell impurities, and large endotoxin aggregates, thereby significantly reducing the purification burden on subsequent chromatography steps. Throughout the entire process, all piping, filters, and buffers should use endotoxin-free materials and be prepared with purified water to prevent secondary contamination and establish a fully controlled, pyrogen-free manufacturing process.
II. Core Chromatographic Purification: Deep and Targeted Removal of Residual Endotoxins
Endotoxin lipopolysaccharides (LPS) carry a strong negative charge and exhibit strong hydrophobicity. Recombinant collagen, with its unique charge properties and three-dimensional structure, can be precisely separated through a combination of chromatographic processes while preserving the integrity of its collagen triple-helix structure.Anion exchange chromatography (AEX) is the primary purification process. Under an appropriate pH buffer system, the strongly negatively charged endotoxins bind tightly to anion exchange media (Q or DEAE columns). By controlling the buffer conductivity and pH, the target recombinant collagen can pass through in flow-through mode, enabling deep removal of lipopolysaccharides at large scale. This process is readily scalable and balances endotoxin removal efficiency with production capacity, making it a critical step in the large-scale production of medical-grade recombinant collagen. A gradient elution step can also be incorporated to dissociate endotoxin aggregates that are non-specifically associated with collagen, thereby further reducing residual endotoxin levels.
Specific affinity-based endotoxin removal chromatography is suitable for ultra-high-specification medical-grade raw materials. Immobilized polymyxin B media can specifically bind the lipid A structure of endotoxins, enabling precise capture of trace lipopolysaccharide impurities and further reducing endotoxin levels to trace levels. Residual polymyxin B must then be strictly tested to avoid secondary risks associated with the excipient. In addition, hydrophobic interaction chromatography (HIC) and mixed-mode chromatography can be combined to simultaneously remove host cell proteins (HCPs), degradation fragments, and endotoxin in the bound state. Size-exclusion chromatography (SEC) can remove endotoxin aggregates based on differences in molecular weight while simultaneously achieving desalting, further improving the homogeneity and stability of the raw material.
It should be noted that strong acids, strong bases, and high concentrations of aggressive detergents can disrupt the three-dimensional structure of the collagen triple helix, resulting in a loss of its repair activity. Therefore, the overall endotoxin removal process should be conducted under mild pH and temperature conditions. Nonionic detergents, such as Triton X-114, can be used for pretreatment of crude products to remove a portion of the endotoxin through phase separation. However, subsequent ultrafiltration must be performed to thoroughly remove detergent residues, and this approach should not be used directly for finished raw materials.
Ⅲ Ultrafiltration/Diafiltration Purification and Buffer Exchange
An appropriate tangential flow filtration (TFF) ultrafiltration cassette with a suitable molecular weight cutoff (MWCO) is used for repeated buffer exchange and diafiltration to remove free low-molecular-weight endotoxins, residual buffer salts, TFA, and other impurities. This process simultaneously achieves concentration and exchange into a pharmaceutical-grade buffer, addressing both endotoxin removal and protein refolding requirements. Where necessary, pharmaceutical-grade activated carbon adsorption can be used for preliminary endotoxin removal. The amount of activated carbon and contact time must be strictly controlled to avoid significant yield loss caused by adsorption of the target collagen.The entire process should be conducted under low-temperature conditions to preserve the triple-helix structure of the collagen and maintain its biological activity. High-temperature sterilization should be avoided, as it may cause protein denaturation and loss of activity.
IV. Quality Control Verification and Sterility Assurance
Batch-by-batch endotoxin testing is performed using the Limulus Amebocyte Lysate (LAL) kinetic turbidimetric assay to ensure consistently compliant endotoxin levels for medical-grade applications. Comprehensive testing is also conducted for purity, residual host cell proteins (HCPs) and host cell DNA, aggregate content, and biological activity. Complete batch records are established to ensure batch-to-batch consistency and reproducibility.
After the product passes all quality control tests, sterile filtration, low-temperature lyophilization, or bulk solution filling is performed under strict GMP conditions with continuous control of pyrogen contamination, thereby preventing the introduction of new endotoxins during subsequent processing. Long-term stability studies are also established to ensure that endotoxin levels remain consistently within specification throughout storage
V. Industry Value and Process Challenges
Many collagen raw materials available on the market undergo only basic filtration, resulting in excessive endotoxin levels and limiting their use to conventional daily skincare applications. They are generally unsuitable for sensitive applications such as post-aesthetic procedures, the eye area, and wound care. Deep endotoxin removal processes achieve two key objectives: first, ensuring long-term skin safety and reducing recurrent redness and sensitivity; and second, preserving the intact collagen triple-helix structure and retaining the core biological activities associated with dermal repair and collagen regeneration, thereby enabling long-term repair rather than merely providing immediate moisturization.
The key process challenge lies in balancing endotoxin removal efficiency, protein recovery, and biological activity. Pursuing extremely low endotoxin levels alone may lead to collagen degradation and collapse of the triple-helix structure, while overly conventional processing may fail to remove endotoxins that are bound to the collagen. A mature end-to-end process can consistently control endotoxin levels below 0.5 EU/mg while maintaining high purity and an intact triple-helix structure, thereby meeting the requirements for medical-device-grade raw materials and supporting the development of the high-end recombinant collagen sector in China.
Conclusion
For high-quality recombinant collagen, half of the equation lies in the gene sequence, while the other half lies in the purification and endotoxin removal process. From upstream strain optimization and pyrogen-controlled fermentation to core purification by anion exchange chromatography, ultrafiltration-based refolding, and rigorous quality control, a mature low-endotoxin process is the key to the large-scale production of medical-grade recombinant collagen and will also serve as a core competitive barrier in the future high-end skin repair and anti-aging market. Only by achieving low endotoxin levels while preserving an intact collagen triple-helix structure and biological activity can recombinant collagen truly deliver gentle, long-lasting dermal repair and meet the requirements for long-term use in post-aesthetic care and highly sensitive skin.
